After a 17.5% decline over one year, Sanofi shares gain 2% during the session
The Parisian pharmaceutical laboratory rebounds in mid-morning trading, within a rising CAC 40 index. This recovery comes after a prolonged decline that has brought it to an unprecedented low in several years.
A rebound that leaves the stock far from its moving averages
The Sanofi share gains 2.03% to €71.41, compared to €69.99 at the previous close, which is the support level the stock broke through on Friday when it touched its lowest level since 2018. The session remains in line with previous ones: the price is 2.50% below its 20-day moving average and 7.82% below its 200-day moving average. Today's rebound therefore does not change the profile of the stock, which is down 6.36% over one month and 17.73% over one year. The RSI at 33 remains close to the oversold zone, following a decline that has spared no recent timeframe.
A P/E of 8.3 on the current fiscal year, in a supported Paris market
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On the basis of expected earnings per share, the consensus of surveyed analysts values the stock at approximately 8.3 times current fiscal year earnings and 7.9 times those of the following year, with expected EPS growth of 5.8%. The stock ranks among the strongest gains in the CAC 40 in mid-morning trading, as the index advances 0.68%. The session is driven by financial stocks and by Eurofins Scientific, which gains 2.81%. The next price reference point is the support level at €69.99, at which the stock has been trading since Friday.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 22 106 millions d'euros
Quarterly revenue: 22 106 millions d'euros
Revenue growth: 11,1 %
Net income: 1 957 millions d'euros
Free cash flow: 3 724 millions d'euros
15 513 millions d'euros
Outlook / guidance
Expected revenue: 47 989 millions d'euros
Management commentary: Sanofi anticipe un taux de croissance autour de 10% à TCC, et prévoit pour le BNPA des activités à TCC une croissance légèrement supérieure à celle des ventes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
